ARTICLE | Emerging Company Profile
Luminary: turning cell engineering tools into therapies
Former B-MoGen execs leverage experience in non-viral cell engineering tools to form therapeutic start-up
August 22, 2020 2:16 AM UTC
Luminary is parlaying its founders’ experience in non-viral genome engineering to build a pipeline of cell therapies that are faster to develop and more cost-effective than those that depend on virus-based technologies.
Luminary Therapeutics Inc. was carved out of B-MoGen Biotechnologies Inc. in 2019 during B-MoGen’s acquisition by research tools and services company Bio-Techne Corp. (NASDAQ:TECH)...